Dynamic Contrast-Enhanced MRI for Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: Initial Results

Diffusion‐weighted and dynamic contrast‐enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients

“…The relative change in MRI measured longest tumor diameter had a high sensitivity and specificity for predicting pathologic response, with only one false positive and one false negative result. MRI has been shown to provide an accurate estimation of tumor size in invasive breast cancer compared with pathological tumor size (27,28) Several other studies of response to NAC in breast cancer patients found that early evaluation of MRI derived tumor diameter was the best predictor of response to NAC, (7,13,(29)(30)(31), although the same relationship was not found in (32).…”

“…Parameters from DCE-MRI have also been investigated as predictors of treatment response, although different methods and approaches have been used (7,(30)(31)(32)36). In the present study, we found a trend to change in the mean and skewness of v e for all patients after treatment.…”

“…Similar publications show discrepancy between the results correlating vascular parameters to response to NAC. Some studies find a clear correlation of parameters such as K trans with response (30,32,36), while others show more moderate results (7,31). Several factors may contribute to explain these varying results.…”

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

“…For HER2-positive tumors, the regimens included ddAC and PTC (paclitaxel 80 mg/m 2 week -1 , trastuzumab 2 mg/kg and carboplatin AUC 2-3 mg/ml min times 6, q 8 weeks) after 2005 [14,15]. After one or three cycles (depending on the specific protocol) the tumor response was evaluated by contrast enhanced MRI [16]. Chemotherapy regimens were changed to a presumably non-cross-resistant regimen when response failure was apparent upon radiological evaluation.…”

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

“…After evaluation, by comparing a repeat contrast-enhanced MRI to a prechemotherapy MRI, patients with favorably responding tumors continued their initial chemotherapy and patients with minimal response or stable disease were switched to the alternative chemotherapy regimen [19]. Most tumors harboring HER2 gene amplifications were treated with trastuzumab and weekly paclitaxel and carboplatin (37 of 43 tumors).…”